PPARA and obesity due to melanocortin 4 receptor deficiency: Experiments conducted on obese mice showed that PPARα agonist treatments improved the obesity condition and glucose homeostasis in terms of glucose intolerance, insulin resistance, and hyperglycemia [42,43].